M&A Deals: Monthly Monitor October
October – There was no slowing down in sight for the merger and acquisition market in October as the autumn chill sets in, giving way to the winters. The appetite is here to stay in the near-term with Ireland-headquartered Allergan (NYSE: AGN) confirming talks with pharma giant Pfizer (NYSE: PFE) regarding a potential business combination transaction.
On the other hand, Shire (LSE: SHP) renewed its vow to go after Baxalta (NYSE: BXLT). The US biotechnology firm Baxalta’s late-stage research in rare blood cancer has been at the heart of the overtures.
Biggest Deal: US drug wholesaler AmerisourceBergen’s (NYSE:ABC) definitive agreement to purchase privately-held PharMEDium Healthcare Holdings, for $2.6 billion in cash was the biggest deal of the month.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze